Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Stroke ; 55(4): 921-930, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38299350

ABSTRACT

BACKGROUND: Transcarotid artery revascularization (TCAR) is an interventional therapy for symptomatic internal carotid artery disease. Currently, the utilization of TCAR is contentious due to limited evidence. In this study, we evaluate the safety and efficacy of TCAR in patients with symptomatic internal carotid artery disease compared with carotid endarterectomy (CEA) and carotid artery stenting (CAS). METHODS: A systematic review was conducted, spanning from January 2000 to February 2023, encompassing studies that used TCAR for the treatment of symptomatic internal carotid artery disease. The primary outcomes included a 30-day stroke or transient ischemic attack, myocardial infarction, and mortality. Secondary outcomes comprised cranial nerve injury and major bleeding. Pooled odds ratios (ORs) for each outcome were calculated to compare TCAR with CEA and CAS. Furthermore, subgroup analyses were performed based on age and degree of stenosis. In addition, a sensitivity analysis was conducted by excluding the vascular quality initiative registry population. RESULTS: A total of 7 studies involving 24 246 patients were analyzed. Within this patient cohort, 4771 individuals underwent TCAR, 12 350 underwent CEA, and 7125 patients underwent CAS. Compared with CAS, TCAR was associated with a similar rate of stroke or transient ischemic attack (OR, 0.77 [95% CI, 0.33-1.82]) and myocardial infarction (OR, 1.29 [95% CI, 0.83-2.01]) but lower mortality (OR, 0.42 [95% CI, 0.22-0.81]). Compared with CEA, TCAR was associated with a higher rate of stroke or transient ischemic attack (OR, 1.26 [95% CI, 1.03-1.54]) but similar rates of myocardial infarction (OR, 0.9 [95% CI, 0.64-1.38]) and mortality (OR, 1.35 [95% CI, 0.87-2.10]). CONCLUSIONS: Although CEA has traditionally been considered superior to stenting for symptomatic carotid stenosis, TCAR may have some advantages over CAS. Prospective randomized trials comparing the 3 modalities are needed.


Subject(s)
Carotid Stenosis , Endarterectomy, Carotid , Stents , Humans , Endarterectomy, Carotid/methods , Endarterectomy, Carotid/adverse effects , Carotid Stenosis/surgery , Carotid Artery, Internal/surgery , Myocardial Infarction/surgery , Stroke/surgery , Endovascular Procedures/methods , Ischemic Attack, Transient/surgery , Cerebral Revascularization/methods , Treatment Outcome , Carotid Artery Diseases/surgery
2.
J Stroke Cerebrovasc Dis ; 33(8): 107820, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38876458

ABSTRACT

OBJECTIVES: In this review, we examine the impact of sex and gender on advanced stroke interventions and end-of-life outcomes after stroke and discuss the current theories, available evidence, and gaps in the literature. METHODS: A scoping review of the literature was conducted to determine gender differences on advanced stroke interventions and end-of-life outcomes after stroke. The study team utilized PubMed to conduct a review of the literature and included research studies related to sex, gender, advanced stroke interventions, and end-of-life outcomes after stroke. The PRISMA process for conducting a scoping review was followed. RESULTS: This review found that although evidence regarding gender differences in advanced stroke interventions and end-of-life care after stroke is disparate, some gender differences do indeed exist. Women are less likely to receive thrombectomy or alteplase, women are more likely to receive palliative care intervention, hospice, and women experience stroke mortality at higher rates. CONCLUSIONS: Gender differences in end-of-life care after stroke are apparent with women experiencing lower rates of life sustaining interventions, and higher rates of mortality, palliative and hospice care. More research is needed to identify variables associated with or responsible for gender differences during advance interventions and end-of-life care after stroke.


Subject(s)
Healthcare Disparities , Palliative Care , Stroke , Humans , Female , Male , Sex Factors , Stroke/therapy , Stroke/mortality , Stroke/diagnosis , Treatment Outcome , Risk Factors , Hospice Care , Terminal Care , Aged , Middle Aged , Health Status Disparities
3.
J Stroke Cerebrovasc Dis ; 33(11): 107854, 2024 Jul 14.
Article in English | MEDLINE | ID: mdl-39004239

ABSTRACT

BACKGROUND: When a patient is disabled after stroke, they require both emotional support and medical management and may require the assistance of a caregiver. Given the often-sudden onset of disability and the complex challenges related to caring for someone after stroke, caregivers can experience a heavy burden. Caregiver burden negatively affects quality of care, quality of life, and physical and psychological health. The impact of gender on caregiver burden has been in many other conditions; however, the association has not yet been thoroughly assessed in stroke. OBJECTIVE: The aim of this paper is to define caregiver burden, discuss how it is assessed, discuss unique aspects of burden for stroke caregivers, and determine the impact of sex and gender on stroke caregiver role and burden. METHODS: A narrative review was performed to synthesize the available literature and explore how the role of sex and gender impact caregiving for patients who have suffered stroke and whether sex and gender of the caregiver contribute to caregiver burden r. RESULTS: Review of the available literature suggests that sex and gender significantly impact caregiving burden following stroke dipropionately affecting women. CONCLUSIONS: Caregiving for patients who have suffered stroke is often provided by women both inside the home and when patients are within institutions. Women who serve as caregivers to stroke patients may be at higher risk of experiencing burden and its negative effects, including emotional strain, anxiety, and/or depression. More research is needed to determine the best ways to provide support for women who act as caregivers for stroke patients to mitigate caregiver burden.

4.
Curr Neurol Neurosci Rep ; 21(7): 34, 2021 05 10.
Article in English | MEDLINE | ID: mdl-33970361

ABSTRACT

PURPOSE OF REVIEW: The menstrual cycle involves recurrent fluctuations in hormone levels and temperature via neuroendocrine feedback loops. This paper reviews the impact of the menstrual cycle on several common neurological conditions, including migraine, seizures, multiple sclerosis, stroke, and Parkinson's disease. RECENT FINDINGS: The ovarian steroid hormones, estrogen and progesterone, have protean effects on central nervous system functioning that can impact the likelihood, severity, and presentation of many neurological diseases. Hormonal therapies have been explored as a potential treatment for many neurological diseases with varying degrees of evidence and success. Neurological conditions also impact women's reproductive health, and the cessation of ovarian function with menopause may also alter the course of neurological diseases. Medication selection must consider hormonal effects on metabolism and the potential for adverse drug reactions related to menstruation, fertility, and pregnancy outcomes. Novel medications with selective affinity for hormonal receptors are desirable. Neurologists and gynecologists must collaborate to provide optimal care for women with neurological disorders.


Subject(s)
Menstrual Cycle , Migraine Disorders , Estrogens , Female , Humans , Menopause , Pregnancy , Women's Health
5.
JAAPA ; 31(5): 29-33, 2018 May.
Article in English | MEDLINE | ID: mdl-29698369

ABSTRACT

The relationship between host and gut microbiota has been the topic of research in recent decades, with particular emphasis on various species of bacteria and their distinct role in health promotion. Early promising research led to the new term probiotic, coined to describe these beneficial bacteria. This early research has laid the foundation for various proposed mechanisms of probiotic effects on health. This article describes current areas of established probiotic use and introduces areas of current investigation, including psychobiotics, which may help patients suffering from psychiatric illness.


Subject(s)
Probiotics/therapeutic use , Forecasting , Humans , Mental Disorders/microbiology
6.
Neurol Clin ; 42(3): 739-752, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38937039

ABSTRACT

The article summarizes the training pathways and vocational opportunities within the field of vascular neurology. It highlights the groundbreaking clinical trials that transformed acute stroke care and the resultant increased demand for readily available vascular neurology expertise. The article emphasizes the need to train a larger number of diverse physicians in the subspecialty and the role of vascular neurologists in improving outcomes across demographic and geographic lines.


Subject(s)
Neurologists , Neurology , Stroke , Humans , Stroke/therapy , Physician's Role
7.
J Neurointerv Surg ; 15(4): 310-314, 2023 Apr.
Article in English | MEDLINE | ID: mdl-35508381

ABSTRACT

BACKGROUND: Selection of appropriate surgical strategy for the treatment of intracranial aneurysms (IA) during pregnancy requires careful consideration of the potential risks to the mother and fetus. However, limited data guide treatment decisions in these patients. We compared the safety profiles of endovascular coiling (EC) and neurosurgical clipping (NC) performed for the treatment of ruptured and unruptured IA during pregnancy and the postpartum period. METHODS: Pregnancy-related or postpartum hospitalizations undergoing surgical intervention for IA were identified from the Nationwide Readmissions Database 2016-2018. Safety outcomes included periprocedural complications, in-hospital mortality, discharge disposition, and 30-day non-elective readmissions. RESULTS: There were 348 pregnancy-related or postpartum hospitalizations that met the study inclusion criteria (mean±SD age 31.8±5.9 years). Among 168 patients treated for ruptured aneurysms, 115 (68.5%) underwent EC and 53 (31.5%) underwent NC; whereas among 180 patients treated for unruptured aneurysms, 140 (77.8%) underwent EC and 40 (22.2%) underwent NC. There were no statistically significant differences in the baseline characteristics between patients undergoing EC versus NC for either ruptured or unruptured aneurysm groups. The outcomes were statistically comparable between EC and NC for both ruptured and unruptured IA, except for a lower incidence of ischemic stroke in patients undergoing EC for ruptured aneurysms (OR 0.12, 95% CI 0.02 to 0.84). CONCLUSIONS: Most pregnant and postpartum patients are treated with EC for both ruptured and unruptured IA. For treatment of ruptured IA, EC is independently associated with a lower risk of perioperative ischemic stroke, but other in-hospital complications and mortality are comparable between EC and NC.


Subject(s)
Aneurysm, Ruptured , Embolization, Therapeutic , Endovascular Procedures , Intracranial Aneurysm , Female , Humans , Pregnancy , Adult , Intracranial Aneurysm/surgery , Intracranial Aneurysm/complications , Treatment Outcome , Surgical Instruments , Hospitalization , Embolization, Therapeutic/adverse effects , Aneurysm, Ruptured/therapy , Endovascular Procedures/adverse effects
8.
Int J Stroke ; 18(4): 445-452, 2023 04.
Article in English | MEDLINE | ID: mdl-35838335

ABSTRACT

BACKGROUND: There are limited data regarding the best management and outcomes of acute stroke during pregnancy and the puerperium. METHODS: Pregnancy-related hospitalizations with age > 18 years were identified from the Nationwide Readmissions Database 2016-2018. The study cohort consisted of all patients with acute stroke and a 5% random sample of the remaining non-stroke hospitalizations. Logistic regression and survival analyses were used to compare the in-hospital outcomes and readmissions in patients with and without acute stroke. RESULTS: There were 11,829,044 pregnancy-related hospitalizations, of which 4057 had acute stroke. The mean ± SD age of the study cohort was 29.0 ± 5.7 years. Among patients with acute ischemic stroke, 60 (3.7%) patients received intravenous thrombolysis and 112 (6.8%) patients underwent endovascular thrombectomy. Among patients with intracranial hemorrhage, 205 (10.5%) patients underwent ventriculostomy and 18 (0.9%) patients underwent decompressive craniotomy. Patients with stroke had longer length of stay (mean: 10.7 vs 2.7 days), higher in-hospital mortality (4.6% vs 0.0001%) and were less likely to discharge home (73.0% vs 98.6%). Non-elective readmission within 90 days of discharge occurred in 14.8% of patients with stroke versus in 3.9% of patients without stroke. Readmissions due to cerebrovascular events occurred in 2.3% of patients with stroke versus in 0.007% of patients without stroke within 1 year of discharge, with mean ± SD time to readmission 66.2 ± 78.0 days. CONCLUSION: Stroke is a serious complication of pregnancy, associated with high morbidity and mortality. Recurrence of stroke occurs in a small proportion of patients, and the risk is highest during the initial 3 months.


Subject(s)
Brain Ischemia , Ischemic Stroke , Stroke , Pregnancy , Female , Humans , Adult , Middle Aged , Young Adult , Stroke/epidemiology , Stroke/therapy , Brain Ischemia/epidemiology , Brain Ischemia/therapy , Hospitals , Postpartum Period , Treatment Outcome , Retrospective Studies
9.
J Am Heart Assoc ; 12(24): e031669, 2023 Dec 19.
Article in English | MEDLINE | ID: mdl-38108256

ABSTRACT

BACKGROUND: Intravenous thrombolysis (IVT) is an effective stroke therapy that remains underused. Currently, the use of IVT in patients with recent direct oral anticoagulant (DOAC) intake is not recommended. In this study we aim to investigate the safety and efficacy of IVT in patients with acute ischemic stroke and recent DOAC use. METHODS AND RESULTS: A systematic review and meta-analysis of proportions evaluating IVT with recent DOAC use was conducted. Outcomes included symptomatic intracranial hemorrhage, any intracranial hemorrhage, serious systemic bleeding, and 90-day functional independence (modified Rankin scale score 0-2). Additionally, rates were compared between patients receiving IVT using DOAC and non-DOAC by a random effect meta-analysis to calculate pooled odds ratios (OR) for each outcome. Finally, sensitivity analysis for idarucizumab, National Institutes of Health Stroke Scale, and timing of DOAC administration was completed. Fourteen studies with 247 079 patients were included (3610 in DOAC and 243 469 in non-DOAC). The rates of IVT complications in the DOAC group were 3% (95% CI, 3-4) symptomatic intracranial hemorrhage, 12% (95% CI, 7-19) any ICH, and 0.7% (95%CI, 0-1) serious systemic bleeding, and 90-day functional independence was achieved in 57% (95% CI, 43-70). The rates of symptomatic intracranial hemorrhage (3.4 versus 3.5%; OR, 0.95 [95% CI, 0.67-1.36]), any intracranial hemorrhage (17.7 versus 17.3%; OR, 1.23 [95% CI, 0.61-2.48]), serious systemic bleeding (0.7 versus 0.6%; OR, 1.27 [95% CI, 0.79-2.02]), and 90-day modified Rankin scale score 0-2 (46.4 versus 56.8%; OR, 1.21 [95% CI, 0.400-3.67]) did not differ between DOAC and non-DOAC groups. There was no difference in symptomatic intracranial hemorrhage rate based on idarucizumab administration. CONCLUSIONS: Patients with acute ischemic stroke treated with IVT in recent DOAC versus non-DOAC use have similar rates of hemorrhagic complications and functional independence. Further prospective randomized trials are warranted.


Subject(s)
Brain Ischemia , Ischemic Stroke , Stroke , Humans , Stroke/diagnosis , Stroke/drug therapy , Fibrinolytic Agents/adverse effects , Ischemic Stroke/diagnosis , Ischemic Stroke/drug therapy , Ischemic Stroke/complications , Thrombolytic Therapy/adverse effects , Thrombolytic Therapy/methods , Brain Ischemia/diagnosis , Brain Ischemia/drug therapy , Brain Ischemia/complications , Hemorrhage/chemically induced , Intracranial Hemorrhages/chemically induced , Intracranial Hemorrhages/epidemiology , Intracranial Hemorrhages/complications , Treatment Outcome , Anticoagulants/adverse effects
10.
Neurology ; 2022 Aug 19.
Article in English | MEDLINE | ID: mdl-35985829

ABSTRACT

OBJECTIVE: To evaluate the frequency, etiologies, and risk factors for 90-day readmissions following hospitalization for PRES. METHODS: Data were obtained from the Nationwide Readmissions Database 2016-2018. Patients with primary diagnosis of PRES, survival to discharge, and known discharge disposition were included. Primary outcome was non-elective readmission within 90 days of discharge. Survival analysis was performed, and independent predictors of readmission were analyzed using multivariable Cox proportional hazards regression. RESULTS: Based on the study inclusion criteria, 6,155 eligible patients were included (mean±SD age: 55.9±17.3 years, female: 71.0%). Non-elective readmission within 90 days of discharge occurred for 1,922 (31.2%) patients. Of these, 617 readmissions were due to PRES-related or neurological etiologies and the remaining 1305 readmissions were due to non-neurological conditions. In multivariable analysis, age was inversely associated with risk of readmission [hazards ratio (HR): 0.92 for every 10 years increase in age, 95% confidence interval (CI): 0.88-0.97]. Patients with diabetes (HR: 1.21, 95% CI: 1.04-1.42), systemic lupus erythematosus (HR: 1.42, 95% CI: 1.03-1.96), acute kidney injury (HR: 1.28, 95% CI: 1.11-1.47) and higher Charlson comorbidity index score (HR: 1.09, 95% CI: 1.06-1.13) were more likely to be readmitted. Further, patients admitted at large bed size hospitals (HR: 1.19, 95% CI: 1.03-1.39), those with longer length of stay (HR: 1.01, 95% CI: 1.00-1.02) and those not discharged to home (HR: 1.33, 95% CI: 1.14-1.55) during the index hospitalization were also at a higher risk for readmission. CONCLUSION: Nearly one-third of patients hospitalized due to PRES are readmitted within 90 days of discharge and about one-third of these readmissions are due to PRES-related or neurological etiologies. Younger age, a higher comorbidity burden, longer length of hospital stay, and discharge disposition other than to home are independently associated with the risk of readmission.

11.
Handb Clin Neurol ; 172: 3-31, 2020.
Article in English | MEDLINE | ID: mdl-32768092

ABSTRACT

Maternal ischemic stroke and cerebral venous sinus thrombosis (CVST) are dreaded complications of pregnancy and major contributors to maternal disability and mortality. This chapter summarizes the incidence and risk factors for maternal arterial ischemic stroke (AIS) and CVST and discusses the pathophysiology of maternal AIS and CVST. The diagnosis, treatment, and secondary preventive strategies for maternal stroke are also reviewed. Special populations at high risk of maternal stroke, including women with moyamoya disease, sickle cell disease, HIV, thrombophilia, and genetic cerebrovascular disorders, are highlighted.


Subject(s)
Brain Ischemia , Ischemic Stroke , Sinus Thrombosis, Intracranial , Stroke , Brain Ischemia/complications , Brain Ischemia/epidemiology , Child , Female , Heparin, Low-Molecular-Weight , Humans , Pregnancy , Sinus Thrombosis, Intracranial/epidemiology , Stroke/epidemiology , Stroke/etiology
12.
Front Neurol ; 11: 805, 2020.
Article in English | MEDLINE | ID: mdl-32754113

ABSTRACT

Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily causes respiratory illness. However, neurological sequelae from novel coronavirus disease 2019 (COVID-19) can occur. Patients with neurological conditions may be at higher risk of developing worsening of their underlying problem. Here we document our initial experiences as neurologic consultants at a single center quaternary hospital at the epicenter of the COVID-19 pandemic. Methods: This was a retrospective case series of adult patients diagnosed with SARS-CoV-2 who required neurological evaluation in the form of a consultation or primary neurological care from March 13, 2020 to April 1, 2020. Results: Thirty-three patients (ages 17-88 years) with COVID-19 infection who required neurological or admission to a primary neurology team were included in this study. The encountered neurological problems associated with SARS-CoV-2 infection were encephalopathy (12 patients, 36.4%), seizure (9 patients, 27.2%), stroke (5 patients, 15.2%), recrudescence of prior neurological disease symptoms (4 patients, 12.1%), and neuromuscular (3 patients, 9.1%). The majority of patients who required evaluation by neurology had elevated inflammatory markers. Twenty-one (63.6%) patients were discharged from the hospital and 12 (36.4%) died from COVID-19 related complications. Conclusion: This small case series of our initial encounters with COVID-19 infection describes a range of neurological complications which are similar to presentations seen with other critical illnesses. COVID-19 infection did not change the overall management of neurological problems.

SELECTION OF CITATIONS
SEARCH DETAIL